viewCytoDyn Inc.

CytoDyn taps Mahboob Rahman as chief scientific officer as it accelerates its clinical and regulatory priorities

The company said Dr Rahman’s industry experience is highlighted by 16 successful new drug applications and BLA requests

CytoDyn Inc. - CytoDyn taps Mahboob Rahman as chief scientific officer as it accelerates its clinical and regulatory priorities
CytoDyn Chief Medical Officer Scott A Kelly said Dr Rahman's "deep knowledge of immunology and successful regulatory experience" would prove invaluable for the company

CytoDyn Inc (OTCQB:CYDY) named industry veteran Mahboob U Rahman its chief scientific officer on Thursday, as the biotechnology company accelerates its clinical and regulatory priorities while developing its lead drug leronlimab (PRO 140) for multiple indications. 

Dr Rahman was the global head of Immunology Development and Pharmacovigilance at Mesoblast Inc (NASDAQ:MESO) (ASX:MSB), a leader in medicines for inflammatory diseases. He has also worked at Pfizer Inc (NYSE:PFE) (FRA:PFE) and was involved in the development of tofacitiniband etanercept. In 2013, he joined Novartis as a VP and the therapeutic area head for Immunology and Musculoskeletal Disease, where he was involved in the development of several compounds of which two — canakinumab and secukinumab — won US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval for marketing in several indications.

CytoDyn Chief Medical Officer Scott A Kelly said: “We are very pleased Dr Rahman has joined our executive team. We expect his deep knowledge of immunology and successful regulatory experience to prove invaluable for patients and our company.”

READ: CytoDyn wins positive DSMC recommendation after interim analysis of leronlimab in Phase 2b/3 COVID-19 trial

Dr Rahman received his medical degree from Dhaka Medical College, Bangladesh and a PhD in molecular biology from the Medical College of Pennsylvania. He completed his internal medicine residency at the Medical College of Pennsylvania, in Philadelphia and rheumatology fellowship at the Massachusetts General Hospital/Harvard Medical School, Boston. He then joined the Harvard Medical School faculty and won an NIH research grant.

While working in the pharmaceutical industry, Dr Rahman has maintained his educational and clinical activities. He was an adjunct professor at University of Pennsylvania School of Medicine from 2002 to 2016 and more recently, a clinical professor at the Rutgers RWJ School of Medicine. He has published more than 100 scientific papers in peer-reviewed journals.

“We believe Dr Rahman’s proven track record in our industry, coupled with his medical and research expertise will undoubtedly help accelerate many of our clinical and regulatory priorities,” said CytoDyn CEO Nader Pourhassan.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter:@UttaraProactive

Quick facts: CytoDyn Inc.


Price: 2.26 USD

Market Cap: $1.43 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


CytoDyn treats first patient with flagship drug in its Phase 3 coronavirus...

CytoDyn Inc CEO Nader Pourhassan tells Proactive it has treated the first patient with its flagship drug candidate leronlimab (Vyrologix or PRO 140) in a pivotal Phase 3 coronavirus trial in Brazil for patients with severe symptoms. Pourhassan says an interim analysis will be conducted 28...

1 week, 4 days ago

2 min read